These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

206 related articles for article (PubMed ID: 22806596)

  • 1. Natural antibodies in normal human serum inhibit Staphylococcus aureus capsular polysaccharide vaccine efficacy.
    Skurnik D; Kropec A; Roux D; Theilacker C; Huebner J; Pier GB
    Clin Infect Dis; 2012 Nov; 55(9):1188-97. PubMed ID: 22806596
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Comparative opsonic and protective activities of Staphylococcus aureus conjugate vaccines containing native or deacetylated Staphylococcal Poly-N-acetyl-beta-(1-6)-glucosamine.
    Maira-Litrán T; Kropec A; Goldmann DA; Pier GB
    Infect Immun; 2005 Oct; 73(10):6752-62. PubMed ID: 16177353
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Opsonic and protective properties of antibodies raised to conjugate vaccines targeting six Staphylococcus aureus antigens.
    Pozzi C; Wilk K; Lee JC; Gening M; Nifantiev N; Pier GB
    PLoS One; 2012; 7(10):e46648. PubMed ID: 23077517
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Animal and human antibodies to distinct Staphylococcus aureus antigens mutually neutralize opsonic killing and protection in mice.
    Skurnik D; Merighi M; Grout M; Gadjeva M; Maira-Litran T; Ericsson M; Goldmann DA; Huang SS; Datta R; Lee JC; Pier GB
    J Clin Invest; 2010 Sep; 120(9):3220-33. PubMed ID: 20739753
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Antibody to a conserved antigenic target is protective against diverse prokaryotic and eukaryotic pathogens.
    Cywes-Bentley C; Skurnik D; Zaidi T; Roux D; Deoliveira RB; Garrett WS; Lu X; O'Malley J; Kinzel K; Zaidi T; Rey A; Perrin C; Fichorova RN; Kayatani AK; Maira-Litràn T; Gening ML; Tsvetkov YE; Nifantiev NE; Bakaletz LO; Pelton SI; Golenbock DT; Pier GB
    Proc Natl Acad Sci U S A; 2013 Jun; 110(24):E2209-18. PubMed ID: 23716675
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Molecular basis for preferential protective efficacy of antibodies directed to the poorly acetylated form of staphylococcal poly-N-acetyl-beta-(1-6)-glucosamine.
    Cerca N; Jefferson KK; Maira-Litrán T; Pier DB; Kelly-Quintos C; Goldmann DA; Azeredo J; Pier GB
    Infect Immun; 2007 Jul; 75(7):3406-13. PubMed ID: 17470540
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Protein antigens increase the protective efficacy of a capsule-based vaccine against Staphylococcus aureus in a rat model of osteomyelitis.
    Lattar SM; Noto Llana M; Denoël P; Germain S; Buzzola FR; Lee JC; Sordelli DO
    Infect Immun; 2014 Jan; 82(1):83-91. PubMed ID: 24126523
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Synthesis and evaluation of a conjugate vaccine composed of Staphylococcus aureus poly-N-acetyl-glucosamine and clumping factor A.
    Maira-Litrán T; Bentancor LV; Bozkurt-Guzel C; O'Malley JM; Cywes-Bentley C; Pier GB
    PLoS One; 2012; 7(9):e43813. PubMed ID: 22970144
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The role of epitope specificity in the human opsonic antibody response to the staphylococcal surface polysaccharide poly N-acetyl glucosamine.
    Kelly-Quintos C; Kropec A; Briggs S; Ordonez CL; Goldmann DA; Pier GB
    J Infect Dis; 2005 Dec; 192(11):2012-9. PubMed ID: 16267775
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Antibodies to Staphylococcus aureus serotype 8 capsular polysaccharide react with and protect against serotype 5 and 8 isolates.
    Park S; Gerber S; Lee JC
    Infect Immun; 2014 Dec; 82(12):5049-55. PubMed ID: 25245803
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Antibodies to Staphylococcus aureus capsular polysaccharides 5 and 8 perform similarly in vitro but are functionally distinct in vivo.
    Liu B; Park S; Thompson CD; Li X; Lee JC
    Virulence; 2017 Aug; 8(6):859-874. PubMed ID: 27936346
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Antibodies to Conserved Surface Polysaccharides Protect Mice Against Bacterial Conjunctivitis.
    Zaidi TS; Zaidi T; Pier GB
    Invest Ophthalmol Vis Sci; 2018 May; 59(6):2512-2519. PubMed ID: 29847658
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Evaluation of serotypes 5 and 8 capsular polysaccharides in protection against Staphylococcus aureus in murine models of infection.
    Cheng BL; Nielsen TB; Pantapalangkoor P; Zhao F; Lee JC; Montgomery CP; Luna B; Spellberg B; Daum RS
    Hum Vaccin Immunother; 2017 Jul; 13(7):1609-1614. PubMed ID: 28422567
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Antigenic determinants of Staphylococcus aureus type 5 and type 8 capsular polysaccharide vaccines.
    Fattom AI; Sarwar J; Basham L; Ennifar S; Naso R
    Infect Immun; 1998 Oct; 66(10):4588-92. PubMed ID: 9746554
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Characterization of the opsonic and protective activity against Staphylococcus aureus of fully human monoclonal antibodies specific for the bacterial surface polysaccharide poly-N-acetylglucosamine.
    Kelly-Quintos C; Cavacini LA; Posner MR; Goldmann D; Pier GB
    Infect Immun; 2006 May; 74(5):2742-50. PubMed ID: 16622211
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Preclinical Efficacy of Clumping Factor A in Prevention of Staphylococcus aureus Infection.
    Li X; Wang X; Thompson CD; Park S; Park WB; Lee JC
    mBio; 2016 Feb; 7(1):e02232-15. PubMed ID: 26838725
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Synthetic {beta}-(1->6)-linked N-acetylated and nonacetylated oligoglucosamines used to produce conjugate vaccines for bacterial pathogens.
    Gening ML; Maira-Litrán T; Kropec A; Skurnik D; Grout M; Tsvetkov YE; Nifantiev NE; Pier GB
    Infect Immun; 2010 Feb; 78(2):764-72. PubMed ID: 19948836
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Protection against Escherichia coli infection by antibody to the Staphylococcus aureus poly-N-acetylglucosamine surface polysaccharide.
    Cerca N; Maira-Litrán T; Jefferson KK; Grout M; Goldmann DA; Pier GB
    Proc Natl Acad Sci U S A; 2007 May; 104(18):7528-33. PubMed ID: 17446272
    [TBL] [Abstract][Full Text] [Related]  

  • 19. A Poly-N-acetylglucosamine-Shiga toxin broad-spectrum conjugate vaccine for Shiga toxin-producing Escherichia coli.
    Lu X; Skurnik D; Pozzi C; Roux D; Cywes-Bentley C; Ritchie JM; Munera D; Gening ML; Tsvetkov YE; Nifantiev NE; Waldor MK; Pier GB
    mBio; 2014 Mar; 5(2):e00974-14. PubMed ID: 24667709
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Vaccination as infection control: a pilot study to determine the impact of Staphylococcus aureus vaccination on nasal carriage.
    Creech CB; Johnson BG; Alsentzer AR; Hohenboken M; Edwards KM; Talbot TR
    Vaccine; 2009 Dec; 28(1):256-60. PubMed ID: 19799842
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.